TABLE 2.
Clinical characteristics of participants grouped by presence of antibodies after matching.
| Group I |
Group II |
Group III |
||
| (n = 104) | (n = 52) | (n = 156) | p a | |
| Age, years | 55 (14) | 58 (13) | 57 (14) | 0.740 |
| Female, n (%) | 90 (86.5) | 50 (96.2) | 135 (86.5) | 0.147 |
| Postmenopause, n (%) | 63 (71.1) | 39 (78) | 105 (77.8) | 0.475 |
| BMI, kg/m2 | 23.8 (5.2) | 22.8 (5.3) | 23 (5.4) | 0.297 |
| Comorbidities +, n (%) | 63 (60.6) | 41 (78.8) | 86 (55.1) | 0.010 |
| RA-related factors + | ||||
| Disease duration, years | 12 (13) | 11.5 (19) | 12 (10) | 0.874 |
| Baseline DAS28-ESR | 2.7 (1.7) | 3.0 (1.6) | 3.3 (1.6) | 0.006 |
| Mean DAS28 at follow-up | 2.8 (1.2) | 2.9 (1.0) | 3.0 (1.2) | 0.233 |
| HAQ-DI | 0.13 (0.66) | 0.25 (1.03) | 0.25 (0.88) | 0.442 |
| ESR, mm/h | 11 (13.8) | 14 (20.3) | 18 (22.8) | <0.001 |
| Fracture-related factorsb + | ||||
| Parent fractured hip +, n (%) | 10 (9.7) | 2 (3.8) | 14 (9.2) | 0.420 |
| Previous fracture +, n (%) | 34 (32.7) | 16 (30.8) | 50 (32.1) | 0.971 |
| Alcohol +, n (%) | 2 (1.9) | 0 (0) | 2 (1.3) | 0.603 |
| Smoking +, n (%) | 4 (3.8) | 0 (0) | 11 (7.1) | 0.103 |
| Secondary osteoporosis +, n (%) | 2 (1.9) | 1 (1.9) | 5 (3.2) | 0.774 |
| Baseline BMD (g/m2) | ||||
| FN | 0.664 ± 0.114 | 0.635 ± 0.118 | 0.624 ± 0.127 | 0.010 |
| TH | 0.818 ± 0.128 | 0.782 ± 0.144 | 0.784 ± 0.148 | 0.053 |
| L1–4 | 0.894 ± 0.167 | 0.868 ± 0.172 | 0.862 ± 0.160 | 0.254 |
| FRAX score | ||||
| Major | 12 (13.9) | 13 (18.6) | 14 (20.7) | 0.214 |
| Hip | 3.4 (6.1) | 4.4 (9.0) | 4.3 (9.3) | 0.049 |
| New incident fracture (3 years), n (%) | 22 (25.3) | 14 (31.1) | 50 (37.6) | 0.159 |
| Osteoporosisc +, n (%) | 16 (15.4) | 16 (30.8) | 49 (31.4) | 0.011 |
| Medications | ||||
| GC + , n (%) | 92 (88.5) | 49 (94.2) | 150 (96.2) | 0.050 |
| b/tsDMARDsd +, n (%) | 10 (9.6) | 11 (21.2) | 35 (22.4) | 0.025 |
| AOTe +, n (%) | 42 (40.4) | 25 (48.1) | 67 (42.9) | 0.658 |
| BP +, n (%) | 31 (73.8) | 21 (84) | 63 (94) | 0.041 |
| RANKLi +, n (%) | 3 (7.1) | 2 (8) | 2 (3) | 0.502 |
Values are presented as mean ± standard deviation, and median (interquartile range), unless otherwise mentioned. BMI, body mass index; DAS28-ESR, disease activity score-28 joint-erythrocyte sedimentation; HAQ-DI, health assessment questionnaire disability index; ESR, erythrocyte sedimentation rate; BMD, bone mineral density; FN, femoral neck; TH, total hip; L1-4, 1st-4th lumbar vertebra; FRAX, fracture risk assessment tool; GC, glucocorticoid; b/tsDMARDs, biologic/target synthetic disease modify anti-rheumatic drugs; AOT, Anti-osteoporotic therapy; BP, bisphosphonate; RANKLi, Receptor activator of nuclear factor-kB ligand inhibitor (denosumab).
+, presence.
aComparison among three groups.
bDefined as in FRAX tool.
cT-score (femoral neck) ≤ −2.5.
dIncluding anti-TNFa (etanercept, adalimumab, golimumab, certolizumab), anti-IL6 receptor (tocilizumab), CTLA4 analog (abatacept), anti-CD 20 (rituximab), and JAK inhibitor (tofacitinib).
eIncluding bisphosphonates, denosumab, teriparatide, and raloxifene during observation period.